Mundipharma has reported results from a randomised, multicentre, Phase III trial of flutiform, a combination of fluticasone propionate and formoterol in a single pressurised metered dose inhaler, to treat paediatric asthma.

Presented at the European Respiratory Society (ERS) annual congress in Munich, Germany, the data showed the efficacy and tolerability of flutiform, over 12 weeks in children with asthma aged five years to less than 12 years.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The 12-week trial’s primary endpoint was change from predose FEV1 (forced expiratory volume; a key measure of lung capacity) at baseline to two-hour postdose FEV1.

The company said that flutiform (50/5µg 2 puffs BID) was superior to fluticasone propionate (50µg 2 puffs BID) and non-inferior compared to the commonly used combination fluticasone propionate/salmeterol (50/25µg 2 puffs BID) for the primary endpoint.

"Flutiform has already been approved as a maintenance therapy for asthma in adults and adolescents and this data suggests it also has the potential to be an important new treatment option for paediatric patients."

The trial also showed flutiform had a similar tolerability profile to fluticasone propionate and fluticasone propionate/salmeterol.

See Also:

Office of Paediatric Allergology, Bialystok, Poland, principle trial investigator Dr Ploszczuk said: "Living with asthma can have a significant impact on many children and our clinical goal is to help them gain control of their disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Flutiform has already been approved as a maintenance therapy for asthma in adults and adolescents and this data suggests it also has the potential to be an important new treatment option for paediatric patients."

In the double-blind, parallel group, multicentre trial, a total of 512 patients aged five years to less than 12 years were randomised 1:1:1 to 12 weeks of treatment with either FP/FORM (100/10µg BID), FP (100µg BID) or fluticasone propionate/salmeterol (FP/SAL) (100/50µg BID).

According to the company, flutiform is not licensed for paediatric use but it is already available in 18 countries across Europe to treat adolescents aged 12 and above and adults with asthma.

The company is dedicated to research and development of new treatment options to help improve the lives of people affected by asthma.

Mundipharma International is licensed by Jagotec, a Skyepharma Group company, as the authorised distributor of the fluticasone/formoterol combination for Europe and most other territories outside Japan and the Americas.